News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,680 Results
Type
Article (14196)
Company Profile (282)
Press Release (252202)
Section
Business (79501)
Career Advice (153)
Deals (13224)
Drug Delivery (35)
Drug Development (50443)
Employer Resources (31)
FDA (5715)
Job Trends (5127)
News (144382)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21636)
ALS (61)
Alzheimer's disease (833)
Antibody-drug conjugate (ADC) (87)
Approvals (5731)
Artificial intelligence (109)
Autoimmune disease (13)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (19)
Breast cancer (142)
Cancer (1310)
Cardiovascular disease (112)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (307)
Cervical cancer (8)
Clinical research (40905)
Collaboration (499)
Compensation (221)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1371)
Denatured (11)
Depression (29)
Diabetes (126)
Diagnostics (1293)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (78)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (82)
Earnings (29683)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48163)
Executive appointments (408)
FDA (6340)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (467)
Gene editing (89)
Generative AI (9)
Gene therapy (232)
GLP-1 (358)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6590)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (58)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (203)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (186)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (116)
MASH (49)
Medical device (2588)
Medtech (2589)
Mergers & acquisitions (6255)
Metabolic disorders (366)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (60)
Neuropsychiatric disorders (23)
Neuroscience (1206)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1559)
Now hiring (21)
Obesity (186)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (107)
Partnered (8)
Patents (111)
Patient recruitment (66)
Peanut (35)
People (25515)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14441)
Phase II (19033)
Phase III (12035)
Pipeline (735)
Podcasts (47)
Policy (38)
Postmarket research (852)
Preclinical (6064)
Press Release (30)
Prostate cancer (55)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (275)
Real estate (1414)
Recruiting (12)
Regulatory (8569)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (91)
Series B (60)
Service/supplier (1)
Sickle cell disease (39)
Southern California (1386)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (35)
United States (12206)
Vaccines (205)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (91)
Last 7 days (461)
Last 30 days (1675)
Last 365 days (20025)
2025 (4858)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17223)
Australia (2919)
California (3545)
Canada (1055)
China (325)
Colorado (138)
Connecticut (143)
Delaware (88)
Europe (37037)
Florida (417)
Georgia (109)
Idaho (16)
Illinois (213)
India (8)
Indiana (85)
Iowa (1)
Japan (71)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (444)
Massachusetts (2802)
Michigan (69)
Minnesota (137)
Mississippi (1)
Missouri (23)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (889)
New Mexico (12)
New York (965)
North Carolina (523)
North Dakota (4)
Northern California (1559)
Ohio (108)
Oklahoma (9)
Oregon (21)
Pennsylvania (678)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1386)
Tennessee (25)
Texas (410)
Utah (48)
Virginia (70)
Washington D.C. (28)
Washington State (321)
Wisconsin (13)
266,680 Results for "larimar therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 4, 2025
·
1 min read
Press Releases
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 25, 2025
·
15 min read
Press Releases
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
January 23, 2025
·
5 min read
Pharm Country
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.
May 30, 2024
·
7 min read
Business
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, reported its first quarter 2024 operating and financial results.
May 9, 2024
·
11 min read
Pharm Country
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the U.S. FDA has removed the partial clinical hold previously placed on the company’s nomlabofusp (CTI-1601) clinical program.
May 20, 2024
·
6 min read
Press Releases
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
October 30, 2024
·
13 min read
Drug Development
Opinion: Larimar Could Compete with Biogen in Friedreich’s Ataxia
Phase II data indicate Larimar Therapeutics’ injectable therapy nomlabofusp could go head-to-head in the market with Biogen’s Skyclarys.
April 21, 2024
·
3 min read
·
Jia Jie Chen
Pharm Country
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Larimar Therapeutics, Inc. announced that members of the company’s management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Biopharma Conference, taking place in Miami Beach, FL from March 11 – 13, 2024.
March 6, 2024
·
1 min read
Business
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.
March 14, 2024
·
12 min read
1 of 26,668
Next